Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadavist vs Magnevist for MRA in Chinese Patients
NCT00395733Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of gadobutrol in vascular disease (2 arms), sponsored by Bayer. Primary endpoint: Number of Vessel Segments Visualized With Diagnostic Quality. Started Oct 2006; status: completed.
02
Drugs
gadobutrol
03
Conditions
vascular disease
Beyond the preview
Go deeper on NCT00395733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395733.